EnteroMedics (ETRM) Shares are Down -14.82%

EnteroMedics (ETRM) : During the past 4 weeks, traders have been relatively bearish on EnteroMedics (ETRM), hence the stock is down -43.7% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -15.27% relative to the S&P 500. The 4-week change in the price of the stock is -44.84% and the stock has fallen -14.82% in the past 1 week.

The stock has recorded a 20-day Moving Average of 29.64% and the 50-Day Moving Average is 43.01%.The 200 Day SMA reached 86.66% EnteroMedics Inc. has dropped 71.95% during the last 3-month period . Year-to-Date the stock performance stands at -94.1%.


Company shares have received an average consensus rating of Hold for the current week EnteroMedics (NASDAQ:ETRM): stock was range-bound between the intraday low of $0.113 and the intraday high of $0.125 after having opened at $0.1209 on Fridays session. The stock finally closed in the red at $0.1209, a loss of -4.64%. The stock remained in the red for the whole trading day. The total traded volume was 6,111,747 shares. The stock failed to cross $0.125 in Fridays trading. The stocks closing price on Thursday was $0.115.

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Companys neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Companys initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *